"Experts, however, were unsure the deal would result in meaningful savings for Americans.

The deal only applies "to one company and one program," said Drew Altman, the president and CEO of KFF, a nonpartisan health policy research group.

Stacie Dusetzina, a health policy professor at Vanderbilt University in Nashville, Tennessee, said direct to consumer sales "are not going to help the average person at all with achieving lower costs."

Typically, with direct to consumer sales, patients must pay out of pocket, rather than use their insurance. Officials didn't say whether people would be able to use their insurance on TrumpRx.

"Most Americans buy drugs through their insurance plan, so that would mainly help the uninsured," Altman said."

;;

"These announcements serve as good PR for the drug companies but are more of a gimmick that only help a very small number of people," Dusetzina said.

"Instead, the average American is likely to be harmed by the broader policies pushed by the Administration, including a 100% tariff on drugs," Dusetzina said of the overall deal.

"This will raise prices for consumers, not lower them."